Analysis and Commentary STEVEN GROSSMAN 2/9/24 Analysis and Commentary STEVEN GROSSMAN 2/9/24 Developing the Alliance’s FY 2025 Recommendations Read More Advocacy at a Glance STEVEN GROSSMAN 2/2/24 Advocacy at a Glance STEVEN GROSSMAN 2/2/24 Negotiations on Final Agriculture/FDA Appropriations Bill Moving Ahead Read More Analysis and Commentary STEVEN GROSSMAN 2/2/24 Analysis and Commentary STEVEN GROSSMAN 2/2/24 FY 24 Funding Is Not Settled; Yet FY 25 Is Coming Soon Read More Advocacy at a Glance STEVEN GROSSMAN 1/26/24 Advocacy at a Glance STEVEN GROSSMAN 1/26/24 What Comes Next in the Congressional Process Read More Analysis and Commentary STEVEN GROSSMAN 1/26/24 Analysis and Commentary STEVEN GROSSMAN 1/26/24 Status of FY 24 and FY 25 Funding for FDA: Addressing Some FAQs Read More Advocacy at a Glance STEVEN GROSSMAN 1/19/24 Advocacy at a Glance STEVEN GROSSMAN 1/19/24 Senate and House Approve 6-week Continuing Resolution Avoiding a Shutdown Read More Advocacy at a Glance STEVEN GROSSMAN 1/12/24 Advocacy at a Glance STEVEN GROSSMAN 1/12/24 FY 24: No Certainty on What Comes Next Read More Analysis and Commentary STEVEN GROSSMAN 1/12/24 Analysis and Commentary STEVEN GROSSMAN 1/12/24 What Happens to FDA If There is a Shutdown Read More Advocacy at a Glance STEVEN GROSSMAN 1/5/24 Advocacy at a Glance STEVEN GROSSMAN 1/5/24 FDA In First Tranche of Agencies Whose CR Expires on January 19 Read More Analysis and Commentary STEVEN GROSSMAN 1/5/24 Analysis and Commentary STEVEN GROSSMAN 1/5/24 No Predetermined Outcome in Budget Negotiations Read More Advocacy at a Glance STEVEN GROSSMAN 12/15/23 Advocacy at a Glance STEVEN GROSSMAN 12/15/23 House Recesses with No Further Action on Appropriations; Senate to Resume Session Next Monday Read More Analysis and Commentary STEVEN GROSSMAN 12/15/23 Analysis and Commentary STEVEN GROSSMAN 12/15/23 Uncertainty, As Well As Risk to FDA in FY24 Appropriations Process Read More Advocacy at a Glance STEVEN GROSSMAN 12/8/23 Advocacy at a Glance STEVEN GROSSMAN 12/8/23 Negotiations on FY 2024 Appropriation Levels Continue Read More Analysis and Commentary STEVEN GROSSMAN 12/8/23 Analysis and Commentary STEVEN GROSSMAN 12/8/23 FDA Funding At Risk In Current Budget Negotiations Read More Advocacy at a Glance STEVEN GROSSMAN 12/1/23 Advocacy at a Glance STEVEN GROSSMAN 12/1/23 FDA Names Chief Scientist Bumpus as Dr. Woodcock’s Successor Read More Analysis and Commentary STEVEN GROSSMAN 12/1/23 Analysis and Commentary STEVEN GROSSMAN 12/1/23 What Must End, Will End. But When and How? Read More Advocacy at a Glance STEVEN GROSSMAN 11/17/23 Advocacy at a Glance STEVEN GROSSMAN 11/17/23 Laddered Continuing Resolution Signed by President Read More Analysis and Commentary STEVEN GROSSMAN 11/17/23 Analysis and Commentary STEVEN GROSSMAN 11/17/23 “Nothing Resolved. Everything Still on the Table.” Read More Analysis and Commentary STEVEN GROSSMAN 11/15/23 Analysis and Commentary STEVEN GROSSMAN 11/15/23 Shutdown Threats: Second Verse Same as the First; FDA Budget Still at Risk Read More Advocacy at a Glance STEVEN GROSSMAN 11/9/23 Advocacy at a Glance STEVEN GROSSMAN 11/9/23 Status of the Continuing Resolution Read More Newer Posts Older Posts
Analysis and Commentary STEVEN GROSSMAN 2/9/24 Analysis and Commentary STEVEN GROSSMAN 2/9/24 Developing the Alliance’s FY 2025 Recommendations Read More
Advocacy at a Glance STEVEN GROSSMAN 2/2/24 Advocacy at a Glance STEVEN GROSSMAN 2/2/24 Negotiations on Final Agriculture/FDA Appropriations Bill Moving Ahead Read More
Analysis and Commentary STEVEN GROSSMAN 2/2/24 Analysis and Commentary STEVEN GROSSMAN 2/2/24 FY 24 Funding Is Not Settled; Yet FY 25 Is Coming Soon Read More
Advocacy at a Glance STEVEN GROSSMAN 1/26/24 Advocacy at a Glance STEVEN GROSSMAN 1/26/24 What Comes Next in the Congressional Process Read More
Analysis and Commentary STEVEN GROSSMAN 1/26/24 Analysis and Commentary STEVEN GROSSMAN 1/26/24 Status of FY 24 and FY 25 Funding for FDA: Addressing Some FAQs Read More
Advocacy at a Glance STEVEN GROSSMAN 1/19/24 Advocacy at a Glance STEVEN GROSSMAN 1/19/24 Senate and House Approve 6-week Continuing Resolution Avoiding a Shutdown Read More
Advocacy at a Glance STEVEN GROSSMAN 1/12/24 Advocacy at a Glance STEVEN GROSSMAN 1/12/24 FY 24: No Certainty on What Comes Next Read More
Analysis and Commentary STEVEN GROSSMAN 1/12/24 Analysis and Commentary STEVEN GROSSMAN 1/12/24 What Happens to FDA If There is a Shutdown Read More
Advocacy at a Glance STEVEN GROSSMAN 1/5/24 Advocacy at a Glance STEVEN GROSSMAN 1/5/24 FDA In First Tranche of Agencies Whose CR Expires on January 19 Read More
Analysis and Commentary STEVEN GROSSMAN 1/5/24 Analysis and Commentary STEVEN GROSSMAN 1/5/24 No Predetermined Outcome in Budget Negotiations Read More
Advocacy at a Glance STEVEN GROSSMAN 12/15/23 Advocacy at a Glance STEVEN GROSSMAN 12/15/23 House Recesses with No Further Action on Appropriations; Senate to Resume Session Next Monday Read More
Analysis and Commentary STEVEN GROSSMAN 12/15/23 Analysis and Commentary STEVEN GROSSMAN 12/15/23 Uncertainty, As Well As Risk to FDA in FY24 Appropriations Process Read More
Advocacy at a Glance STEVEN GROSSMAN 12/8/23 Advocacy at a Glance STEVEN GROSSMAN 12/8/23 Negotiations on FY 2024 Appropriation Levels Continue Read More
Analysis and Commentary STEVEN GROSSMAN 12/8/23 Analysis and Commentary STEVEN GROSSMAN 12/8/23 FDA Funding At Risk In Current Budget Negotiations Read More
Advocacy at a Glance STEVEN GROSSMAN 12/1/23 Advocacy at a Glance STEVEN GROSSMAN 12/1/23 FDA Names Chief Scientist Bumpus as Dr. Woodcock’s Successor Read More
Analysis and Commentary STEVEN GROSSMAN 12/1/23 Analysis and Commentary STEVEN GROSSMAN 12/1/23 What Must End, Will End. But When and How? Read More
Advocacy at a Glance STEVEN GROSSMAN 11/17/23 Advocacy at a Glance STEVEN GROSSMAN 11/17/23 Laddered Continuing Resolution Signed by President Read More
Analysis and Commentary STEVEN GROSSMAN 11/17/23 Analysis and Commentary STEVEN GROSSMAN 11/17/23 “Nothing Resolved. Everything Still on the Table.” Read More
Analysis and Commentary STEVEN GROSSMAN 11/15/23 Analysis and Commentary STEVEN GROSSMAN 11/15/23 Shutdown Threats: Second Verse Same as the First; FDA Budget Still at Risk Read More
Advocacy at a Glance STEVEN GROSSMAN 11/9/23 Advocacy at a Glance STEVEN GROSSMAN 11/9/23 Status of the Continuing Resolution Read More
